BLA 761025 · Boehringer Ingelheim
Praxbind
Idarucizumab · Injection · Humanized Monoclonal Antibody Fragment
NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Feb 11, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2015
Oct 16, 2015
Approved uses
2
Original approval plus efficacy supplements
Registered trials
8
4 Phase 3, 0 recruiting
FAERS reports
1,434
1,398 serious, 899 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jan 23, 2024.
PRAXBIND is indicated in patients treated with Pradaxa when reversal of the anticoagulant effects of dabigatran is needed: For emergency surgery/urgent procedures In life-threatening or uncontrolled bleeding PRAXBIND is a humanized monoclonal antibody fragment (Fab) indicated in patients treated with Pradaxa ® when reversal of the anticoagulant effects of dabigatran is needed: For emergency surgery/urgent procedures In life-threatening or uncontrolled bleeding ( 1 )
Mechanism: Idarucizumab is a specific reversal agent for dabigatran. It is a humanized monoclonal antibody fragment (Fab) that binds to dabigatran and its acylglucuronide metabolites with higher affinity than the binding affinity of dabigatran to thrombin, neutralizing their anticoagulant effect.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 12, 2018 Supplement 2 · Efficacy OrphanLabelLetter
- Oct 16, 2015 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyAccelerated approvalLabelReviewLetter
1 products under this application
- PRAXBIND · IDARUCIZUMAB 2.5G/50ML · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Idarucizumab" as an intervention, any sponsor and status, largest first.
- Reversal of Dabigatran Anticoagulant Effect With IdarucizumabPivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT02104947 · 503 participants · Start May 6, 2014 · Primary completion Jul 25, 2016
Drug: idarucizumab · For: Hemorrhage
Sites: Little Rock, Arkansas; Loma Linda, California; Washington D.C., District of Columbia · 176 sites in all
- Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BI 655075 Administered Alone or With Dabigatran EtexilatePivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT01688830 · 157 participants · Start Sep 2012 · Primary completion Nov 2013
Drug: Dabigatran; BI 655075 and 1 more · For: Healthy
Sites: Antwerp, Belgium
Boehringer IngelheimBoehringer Ingelheim
NCT02028780 · 80 participants · Start Jan 2014 · Primary completion Aug 2014
Drug: Placebo to dose; Idarucizumab and 3 more · For: Healthy
Sites: Sumida-ku, Tokyo, Japan
Boehringer IngelheimBoehringer Ingelheim
NCT01955720 · 46 participants · Start Sep 2013 · Primary completion May 2014
Drug: BI 655075; BI 655075 and 6 more · For: Hemorrhage
Sites: Antwerp, Belgium
- This Study Looks at the Effects of Idarucizumab in Patients Who Take Dabigatran and Need Emergency Surgery or Are BleedingPivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT03343704 · 19 participants · Start Mar 26, 2018 · Primary completion Jul 2, 2020
Drug: Idarucizumab · For: Hemorrhage
Sites: Beijing, China; Dalian, China; Guangzhou, China · 13 sites in all
Boehringer IngelheimBoehringer Ingelheim
NCT03086356 · 12 participants · Start May 10, 2017 · Primary completion Sep 12, 2017
Drug: Dabigatran etexilate; Idarucizumab · For: Healthy Volunteers
Sites: Beijing, China
- CU Programme of Idarucizumab for Japanese PatientsPivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT02831660 · 1 participants · Start Jul 22, 2016 · Primary completion Sep 16, 2016
Drug: idarucizumab · For: Hemorrhage
Sites: Fukuoka, Kasuga, Japan
- Reversal Dabigatran Anticoagulant Effect With IdarucizumabPivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT02815670 · 1 participants · Start Sep 7, 2016 · Primary completion Oct 19, 2019
Drug: Idarucizumab · For: Hemorrhage
Sites: Kazan', Russia; Tyumen, Russia
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- death170
- haemorrhage119
- gastrointestinal haemorrhage81
- cerebral haemorrhage80
- haemorrhage intracranial67
- drug ineffective64
- multiple organ dysfunction syndrome62
- acute kidney injury48
- sepsis46
- ischaemic stroke45
- pneumonia41
- shock haemorrhagic41
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2015 | 6 |
| 2016 | 114 |
| 2017 | 207 |
| 2018 | 309 |
| 2019 | 274 |
| 2020 | 167 |
| 2021 | 140 |
| 2022 | 71 |
| 2023 | 69 |
| 2024 | 40 |
| 2025 | 24 |
| 2026 | 13 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Reversal of direct oral anticoagulants: Guidance from the Anticoagulation Forum.
Cuker A, Burnett A, Triller D, et al. · Am J Hematol 2019 · Research Support, Non-U.S. Gov't, Systematic Review
- Thrombosis and Coagulopathy.
Savi M, Hawryluk G · Neurosurg Clin N Am 2025 · Systematic Review
- Idarucizumab for Dabigatran Reversal.
Pollack CV, Reilly PA, Eikelboom J, et al. · N Engl J Med 2015 · Clinical Trial, Multicenter Study
- Practical considerations on anticoagulation reversal: spotlight on the reversal of dabigatran.
Giannandrea D, Mengoni A, Carluccio E, et al. · Vasc Health Risk Manag 2019 · Systematic Review
- Idarucizumab for dabigatran reversal: A systematic review and meta-analysis of indications and outcomes.
van der Horst SFB, Martens ESL, den Exter PL, et al. · Thromb Res 2023 · Meta-Analysis, Systematic Review
- Idarucizumab for Reversing Dabigatran-Induced Anticoagulation: A Systematic Review.
Thibault N, Morrill AM, Willett KC · Am J Ther 2018 · Systematic Review
Sponsor: Boehringer Ingelheim
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.